Peripartum neuraxial analgesia may not be associated with an increased risk for multiple sclerosis relapse.
Researchers compared long-term information-processing efficiency between patients with pediatric-onset MS and those with adult-onset MS in a longitudinal cohort study.
Dimethyl fumarate induced changes in the multiple sclerosis lymphocyte repertoire, indicating that lymphocyte subset monitoring is not required for safety vigilance.
Simvastatin’s beneficial effects on clinical outcomes and brain atrophy in patients with multiple sclerosis (MS) are largely independent of cholesterol levels.
The FDA has approved an expanded indication for Emflaza (deflazacort; PTC Therapeutics, Inc.) to include children 2 to 5 years of age with Duchenne muscular dystrophy.
The FDA has accepted for review the New Drug Application (NDA) for ozanimod (Celgene), an investigational treatment for relapsing forms of multiple sclerosis (MS).
The International Pediatric Multiple Sclerosis Study Group has updated standards for future clinical trials in pediatric multiple sclerosis.
A recently published report describes the case of a 69-year-old female patient with cobalamin deficiency who was mistakenly diagnosed with primary progressive multiple sclerosis (PPMS).
Research shows the Multiple Sclerosis Flowsheet database has demonstrated acceptability among staff and clinicians.
The investigators of this Phase 3 study sought to evaluate the efficacy and safety of ADS-5102 (amantadine) extended-release capsules to treat multiple sclerosis patients with walking impairment.